Paydas Semra, Bagir Emine Kilic, Deveci Mehmet Ali, Gonlusen Gulfiliz
Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey.
Department of Pathology, Faculty of Medicine, Cukurova University, Adana, Turkey.
Med Oncol. 2016 Aug;33(8):93. doi: 10.1007/s12032-016-0807-z. Epub 2016 Jul 15.
Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are new targets in cancer immunotherapy in recent years. The aim of this study is to evaluate the PD-1/PD-L1 expressions in sarcomas and to determine association between PD-1/PD-L1 expressions and clinical/pathological properties in some sarcoma subtypes. Formalin-fixed, paraffin-embedded tissue samples from 65 cases with sarcomas were analyzed. Immunohistochemical staining was performed to detect the PD-1 and PD-L1 expressions in tumor tissue and microenvironment, separately. PD-1 expression in tumor tissue and microenvironment was detected in 11 (17 %) and 8 (12 %) cases, respectively. PD-L1 expression in tumor tissue and microenvironment was detected in 19 (29 %) and 20 cases (30 %), respectively. None of the 5 Ewing sarcomas involving bone showed PD-1/PD-L1 expression, while 2 of 3 cases with Ewing sarcomas involving soft tissue showed PD-1 and PD-L1 expression. Among 5 cases with Kaposi sarcoma, four showed PD-1 and/or PD-L1 expression in tumor or microenvironment. PD-1/PD-L1 expressions were detected 3 of 6 cases with pleomorphic sarcoma, 2 of 4 cases with peripheral nerve sheath tumors and 1 of 4 cases with synovial sarcoma. Interestingly, strongest PD-1/PD-L1 expressions in our study group were detected in 2 sarcoma cases with the history of giant cell tumor. PD-1 and PD-L1 expressions are up to 30 % of the cases with sarcomas. It may be rational to target programmed death pathway in Kaposi sarcoma, pleomorphic sarcoma and peripheral nerve sheath tumors. Strong expression of PD-1/PD-L1 in cases with previous giant cell bone tumor has been found to be interesting and must be studied in giant cell tumor samples.
程序性死亡受体1（PD-1）和程序性死亡配体1（PD-L1）是近年来癌症免疫治疗中的新靶点。本研究旨在评估肉瘤中PD-1/PD-L1的表达情况，并确定某些肉瘤亚型中PD-1/PD-L1表达与临床/病理特征之间的关联。分析了65例肉瘤患者经福尔马林固定、石蜡包埋的组织样本。分别采用免疫组织化学染色检测肿瘤组织和微环境中PD-1和PD-L1的表达。肿瘤组织和微环境中PD-1表达分别在11例（17%）和8例（12%）中检测到。肿瘤组织和微环境中PD-L1表达分别在19例（29%）和20例（30%）中检测到。5例累及骨骼的尤因肉瘤均未显示PD-1/PD-L1表达，而3例累及软组织的尤因肉瘤中有2例显示PD-1和PD-L1表达。在5例卡波西肉瘤中，4例在肿瘤或微环境中显示PD-1和/或PD-L1表达。6例多形性肉瘤中有3例、4例周围神经鞘瘤中有2例、4例滑膜肉瘤中有1例检测到PD-1/PD-L1表达。有趣的是，在我们的研究组中，2例有巨细胞瘤病史的肉瘤病例检测到最强的PD-1/PD-L1表达。肉瘤病例中PD-1和PD-L1表达高达30%。针对卡波西肉瘤、多形性肉瘤和周围神经鞘瘤中的程序性死亡途径可能是合理的。已发现既往有巨细胞骨肿瘤的病例中PD-1/PD-L1的强表达很有趣，必须在巨细胞瘤样本中进行研究。
